Galera Therapeutics Current Valuation vs. Book Value Per Share
| GRTXDelisted Stock | USD 2.58 0.19 6.86% |
For Galera Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Galera Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Galera Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Galera Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Galera Therapeutics over time as well as its relative position and ranking within its peers.
Galera |
Galera Therapeutics Book Value Per Share vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Galera Therapeutics's current stock value. Our valuation model uses many indicators to compare Galera Therapeutics value to that of its competitors to determine the firm's financial worth. Galera Therapeutics is rated # 4 in current valuation category among its peers. It is rated below average in book value per share category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Galera Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Galera Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Galera Current Valuation vs. Competition
Galera Therapeutics is rated # 4 in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 1.72 Billion. Galera Therapeutics holds roughly 146.68 Million in current valuation claiming about 9% of equities under Health Care industry.
Galera Book Value Per Share vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Galera Therapeutics |
| = | 146.68 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Galera Therapeutics |
| = | (2.48) X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Galera Book Value Per Share Comparison
Galera Therapeutics is currently under evaluation in book value per share category among its peers.
Galera Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Galera Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Galera Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Galera Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Galera Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Galera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.
Galera Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Galera Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Galera Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Galera Therapeutics' important profitability drivers and their relationship over time.
Use Galera Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Galera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Galera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Galera Therapeutics Pair Trading
Galera Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Galera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Galera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Galera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Galera Therapeutics to buy it.
The correlation of Galera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Galera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Galera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Galera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Galera Therapeutics position
In addition to having Galera Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Information Technology ETFs Thematic Idea Now
Information Technology ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Information Technology ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Information Technology ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Galera Pink Sheet
If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |